Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development

CFDA 93.388 Active Cooperative Agreements (Discretionary Grants)
No open Grants.gov opportunities under this program right now. Browse all Department of Health and Human Services programs →

Program Funding

Annual program obligations reported to SAM.gov.

Latest annual funding (estimated)
$50K FY2024
$500K
FY22
$500K
FY23*
$50K
FY24*
* estimated

Program Objective

The purpose of this program is to coordinate the acceleration of countermeasure and product advanced research and development by—(A) facilitating collaboration between the Department of Health and Human Services and other Federal agencies, relevant industries, academia, and other persons, with respect to such advanced research and development; (B) promoting countermeasure and product advanced research and development; (C) facilitating contacts between interested persons and the offices or employees authorized by the Secretary to advise such persons regarding requirements under the Federal Food, Drug, and Cosmetic Act and under section 351 of the Public Health Service Act; and (D) promoting innovation to reduce the time and cost of countermeasure and product advanced research and development. The Public Health Service Act at 42 U.S.C. 247d-6a defines a qualified countermeasure as “…a drug (as that term is defined by section 321(g)(1) of title 21), biological product (as that term is defined by section 262(i) of this title), or device (as that term is defined by section 321(h) of title 21), that the Secretary determines to be a priority (consistent with sections 182(2) and 184(a) of title 6) to - (i) diagnose, mitigate, prevent, or treat harm from any biological agent (including organisms that cause an infectious disease) or toxin, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security; or (ii) diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device that is used as described in this subparagraph”

Eligibility

Eligible Applicants

  • U.S. territories
  • State
  • State governments
  • Local governments
  • Public nonprofits
  • U.S. territories (incl. universities)
  • Non-government (general)
  • Private nonprofits
  • Quasi-public nonprofits
  • Native American organizations
  • Anyone / general public

All types of entities are eligible, including highly qualified foreign nationals outside the United States either alone or in collaboration with American participants when such transactions may inure to the benefit of the American people. Applicants should review the individual funding opportunity announcements issued under this CFDA program.

How to Apply

Application Procedure

CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program.
Grant applications and required forms for this program can be obtained through Grants.gov – FIND, http://www.grants.gov/. Applicants should visit Grants.gov - FIND for the funding opportunity announcement and Grants.gov - APPLY to download application materials to complete and submit their applications in accordance with the funding opportunity announcement (FOA).

Award Procedure

Applications that successfully proceed through initial screening (as outlined in the funding opportunity announcement) will be objectively reviewed based upon the review criteria specified in the FOA. Applications selected for funding will be processed and the applicant notified in writing through the issuance of a Notice of Award from the Office of the Assistant Secretary for Preparedness and Response.

Decision Timeline

  • Approval: From 30 to 60 days
Program details & compliance

Use of Funds

Allowed Uses

Support international in-country and domestic advanced development and industrialization of human pandemic influenza vaccine. Support activities related to the mitigation of the global shortage of influenza vaccines through awards and sub-awards to developing countries with the potential and capacity to manufacture various influenza vaccines.Basic research (e.g. scientific or medical experiments) is not allowable.100% of funds are for discretionary activities.

Required Documentation

Applicants should review the individual funding opportunity announcements issued under this CFDA program for any credentials or certifications that must be submitted prior to or simultaneous with submission of an application package. 2 CFR 200, Subpart E - Cost Principles applies to this program.

Reporting & Compliance

Audit Required
Yes

Applicable 2 CFR 200 Subparts

  • Subpart B — General Provisions
  • Subpart C — Pre-Federal Award Requirements
  • Subpart D — Post-Federal Award Requirements
  • Subpart E — Cost Principles
  • Subpart F — Audit Requirements

Contacts

Virginia Simmons
202-260-0400
400 7th St SW Constitutional Center, Washington, DC 20024
Data from SAM.gov Federal Assistance Listings. Source published: 2023-12-12. Spec v1.0. Last synced: 2026-06-02 02:44:14.